Wockhardt Ltd said on Thursday it has received approval from United States Food & Drug Administration for marketing antibiotic, Clarithromycin tablets, in the US market.
The company's US subsidiary, Wockhardt USA Inc is expected to launch the antibiotic, used for treating infections caused by bacteria like pneumonia and bronchitis, within the next two weeks, the company informed the Bombay Stock Exchange.
"This is our second ANDA approval in the last two weeks and our fourth this year. With more approvals expected in the second half of 2006, we will have a healthy basket of products in the US," company's Chairman Habil Khorakiwala said.
After receiving the approval for Clarithromycin, the generic version of Abbott's Biaxin tablets, the company now has 13 products in the US market, compared to five last year.
Over 20 products of the company are awaiting USFDA approval.
The shares of the company were trading at Rs 377, up 4.68 per cent at the BSE.
Do you want to discuss stock tips? Do you know a hot one? Join the Stock Market Investments Discussion Group
© 2025